AbbVie's SKINVIVE Gets FDA Nod for Neck Lines, Aiding Aesthetics Turnaround

What happened

Allergan Aesthetics, an AbbVie subsidiary, received FDA approval for SKINVIVE by JUVÉDERM to reduce horizontal neck lines, the first HA injectable for this indication. The approval extends the brand's utility beyond cheek smoothness, addressing 'tech-neck' and aging concerns. This is a modest but positive step for AbbVie's aesthetics segment, which saw FY2025 sales decline 6.1% to $4.86B, with Juvederm dropping 10.7% in Q4 2025. The master report's bear case hinged on aesthetics not stabilizing; this approval supports the bull case of flat to modest growth. However, the revenue contribution from neck lines is likely small, and competitive pressure remains structural. The near-term impact on overall aesthetics revenue is limited, but it signals lifecycle management that could help moderate declines.

Implication

Investors should see this as a small step toward stabilizing the aesthetics segment, which is critical for achieving the $5.0B 2026 guide. However, the core thesis still hinges on Skyrizi/Rinvoq immunology performance and Rinvoq exclusivity. This approval reduces downside risk in the bear case but does not warrant upgrading the rating until broader aesthetics trends improve and immunology confirms its growth trajectory.

Thesis delta

The approval modestly supports the bull case scenario (20% probability, $255 implied value) by providing a new indication to offset Juvederm's decline. However, it does not alter the base case ($235, 55% probability) or the WAIT rating, as the aesthetics overhang remains significant. The key shift is that management now has a tangible product to address Juvederm erosion, potentially improving the segment's trajectory from a -6.1% decline to flat or better, but this is not yet proven.